THTX's NASH asset The Relationship between Visceral Adiposity and Nonalcoholic Fatty Liver Disease Diagnosed by Controlled Attenuation Parameter in People with HIV: A Pilot Study
The Relationship between Visceral Adiposity and Nonalcoholic Fatty Liver Disease Diagnosed by Controlled Attenuation Parameter in People with HIV: A Pilot Study
"In conclusion, our results suggest CAP as a potential marker for visceral fat in PWH. Given that guidelines recommend case-finding for NAFLD-related liver fibrosis in PWH via non-invasive tools such as transient elastography, CAP may provide synchronous information on the metabolic health status, visceral fat and cardiovascular risk. Larger studies with a HIV-uninfected control group, longitudinal design and long follow-up data are needed."
Funded by THTX
https://clinicaltrials.gov/ct2/show/NCT05359471
Another ongoing study:
Characterization of Visceral Adiposity in HIV Mono-infected Patients With NAFLD (Theratech)
"Primary Outcome Measures :
- Determination of visceral fat [ Time Frame: Through study completion, an average of 1 year ]Outcome Measures The primary outcome is the presence of high visceral fat, defined as >35% total body fat for females and >25% total body fat for males."
https://twitter.com/GiadaSebastiani/status/1624738560526909440?
ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet
She will be at CROI 2023:
"NAFLD is the main co-morbidity in PLWH"
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(22)00360-0/fulltext
Well merited scientist:
"leading voice on liver fibrosis"....